AlphAIalphai — Financial news for AI agents
simplywall.stAUG 166 min read$CLBT

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

Original reporting
simplywall.st
Published Aug 16, 2026, 1:34 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 16, 2026, 10:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMarket movers
Primary signal
$CLBT
Bearish
medium confidence
Mentioned
$CLBT
Relevance
8/10
alphai data visualization · based on simplywall.st
Decision brief

The 30-second read

$CLBTBearishMed
01

Why it matters

Investors are likely to focus on whether delayed federal contracts and softer profitability reduce the credibility of the company’s recurring-revenue and AI monetization story.

02

Market read

A guidance reset tied to delayed government contracts is a direct catalyst for repricing CLBT’s near-term revenue visibility and execution risk.

03

What to watch

CEO transition could be a planned succession rather than a deterioration signal; the article also notes AI/cloud investment conversion risk, but does not provide new contract award details to confirm deterioration.

Relevance 8/10Novelty 7/10Timing: post-guidance cut and CEO transition, driving near-term repricing

Background

The piece follows Cellebrite DI’s half-year 2026 results, a lowered full-year revenue outlook, and an announced CEO transition.

Company-level read

Ticker impact

$CLBTBearishMedium confidence
Context

Cellebrite DI cut its 2026 revenue outlook to $555M-$561M and flagged delayed large government contracts, pressuring the near-term catalyst.

Expected impact

Bearish bias for the next several weeks as investors reprice execution and federal procurement timing risk.

Evidence & confidence

The article’s newest concrete facts are the lowered 2026 revenue outlook and CEO transition, both tied to execution and delayed federal deals, which typically drive multiple compression and higher discount rates on forecasted ARR.

Market effects

Sector

Highlights execution risk for digital investigation and AI/cloud vendors reliant on federal procurement cycles.

Regional

Primarily US government contracting exposure narrative, with potential spillover to other defense and public-sector tech names.

Global

Limited direct global read-through beyond government-contract timing and AI monetization expectations.

Counterpoint

What could challenge this read

The revenue range still implies 17%-18% growth, so the cut may reflect timing rather than demand destruction, leaving upside if delayed contracts slip back into 2026.

Key entities

  • public_company
    Cellebrite DI Ltd.

    Subject of the article, with lowered 2026 revenue guidance and a planned CEO transition.

  • person
    Shiven Ramji

    Named successor CEO who will join the board.

  • person
    Thomas E. Hogan

    Outgoing CEO referenced in the planned transition.

Read at source← All news

Related articles

AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min
AUG 14
$CLBTMedAI 8/10

Kaplan Fox is Investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for Potential Securities Law Violations

Kaplan Fox said it is investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for potential securities law violations. The firm cited Cellebrite’s Aug. 13, 2026 Q2 results: ARR of $507.8 million, below prior guidance, and a full-year ARR guidance cut of about $15 million at the midpoint, plus a CEO change replacing Tom Hogan with Shiv Ramji. CLBT shares fell about 29% to $10.80.

theglobeandmail.com4 min
AUG 14
$CLBTMed

Cellebrite DI (CLBT) Names Shiven Ramji CEO As Revenue Guidance Is Cut

Cellebrite DI (NasdaqGS: CLBT) announced CEO succession, naming Shiven Ramji, President, Products and Technology, to become CEO. The company also revised its full-year revenue guidance downward versus its prior outlook and reshaped board responsibilities for the transition. The changes affect investors focused on its recurring subscription revenue model.

simplywall.st3 min